Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?

European Journal of Cancer

Volumn 47, Issue 16, 2011, Pages 2431-2445

  Anninga, Jakob K ^a   Gelderblom, Hans ^a   Fiocco, Marta ^a   Kroep, Judith R ^a   Taminiau, Antoni H M ^a   Hogendoorn, Pancras C W ^a   Egeler, R Maarten ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adriamycin; Bone; Bone neoplasm; Chemotherapy; Cisplatin; Ifosfamide; Methotrexate; Osteosarcoma; Pathological response; Review

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE;

ADD ON THERAPY; ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL STUDY; DRUG EFFICACY; HUMAN; META ANALYSIS; OSTEOSARCOMA; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

AGE FACTORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; MALE; METHOTREXATE; OSTEOSARCOMA; SURVIVAL ANALYSIS;

EID: 80054914908     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.05.030     Document Type: Article

References (142)

1. A.K. Raymond, A.G. Ayala, and K. Knuutila Conventional osteosarcoma C.D.M. Fletcher, K.K. Unni, F. Mertens, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone 2002 IARC Press Lyon 264 270
2. C.A. Stiller, S.S. Bielack, G. Jundt, and E. Steliarova-Foucher Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project Eur J Cancer 42 13 2006 2124 2135
3. L. Mirabello, R.J. Troisi, and S.A. Savage International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons Int J Cancer 125 1 2009 229 234
4. L. Mirabello, R.J. Troisi, and S.A. Savage Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program Cancer 115 7 2009 1531 1543
5. M. Campanacci, and G. Cervellati Osteosarcoma: A review of 345 cases Ital J Orthop Traumatol 1 1 1975 5 22
6. G. Uribe-Botero, W.O. Russell, W.W. Sutow, and R.G. Martin Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54 Am J Clin Pathol 67 5 1977 427 435 (Pubitemid 8107840)
7. P. Cohen Osteosarcoma of the long bones. Clinical observations and experiences in the Netherlands Eur J Cancer 14 9 1978 995 1004 (Pubitemid 9026375)
8. Mulder JD, Schütte HE, Kroon HM, Taconis WK. Radiologic atlas of bone tumors. 2 ed. Amsterdam, Elsevier, 1993.
9. Unni KK. Dahlin's Bone Tumors General Aspects and Data on 11,087 Cases. 5th ed. Philadelphia, Lippincott-Raven Publishers, 1996.
10. S.S. Bielack, B. Kempf-Bielack, and G. Delling Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1, 702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols J Clin Oncol 20 3 2002 776 790 (Pubitemid 34111386)
11. C.A. Stiller, A.W. Craft, and I. Corazziari Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE study Eur J Cancer 37 6 2001 760 766 (Pubitemid 32304412)
12. G. Gatta, R. Capocaccia, M.P. Coleman, L.A. Ries, and F. Berrino Childhood cancer survival in Europe and the United States Cancer 95 8 2002 1767 1772
13. G. Gatta, R. Capocaccia, and C. Stiller Childhood cancer survival trends in Europe: a EUROCARE Working Group study J Clin Oncol 23 16 2005 3742 3751
14. C. Magnani, G. Pastore, and J.W. Coebergh Trends in survival after childhood cancer in Europe, 1978-1997: report from the Automated Childhood Cancer Information System project (ACCIS) Eur J Cancer 42 13 2006 1981 2005 (Pubitemid 44224052)
15. C.A. Stiller, S.J. Passmore, and M.E. Kroll Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980-1994 Br J Cancer 94 1 2006 22 29 (Pubitemid 43088536)
16. G. Gatta, G. Zigon, and R. Capocaccia Survival of European children and young adults with cancer diagnosed 1995-2002 Eur J Cancer 45 6 2009 992 1005
17. M. Fiocco, H. Putter, and J.C. Van Houwelingen A new serially correlated gamma-frailty process for longitudinal count data Biostatistics 10 2 2009 245 257
18. M.K. Parmar, V. Torri, and L. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 24 1998 2815 2834 (Pubitemid 28562978)
19. M. Fiocco, H. Putter, and J.C. Van Houwelingen Meta-analysis of pairs of survival curves under heterogeneity: a Poisson correlated gamma-frailty approach Stat Med 28 30 2009 3782 3797
20. E.P. Cortes, J.F. Holland, and O. Glidewell Amputation and adriamycin in primary osteosarcoma: a 5-year report Cancer Treat Rep 62 2 1978 271 277 (Pubitemid 8287342)
21. M. Campanacci, G. Bacci, and F. Bertoni The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli Cancer 48 7 1981 1569 1581 (Pubitemid 12199416)
22. N. Jaffe, E. Smith, H.T. Abelson, and E. Frei III Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy J Clin Oncol 1 4 1983 251 254 (Pubitemid 14189664)
23. M.P. Link, A.M. Goorin, and A.W. Miser The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity N Engl J Med 314 25 1986 1600 1606 (Pubitemid 16118216)
24. J.F. Huth, and F.R. Eilber Patterns of recurrence after resection of osteosarcoma of the extremity. Strategies for treatment of metastases1 Arch Surg 124 1 1989 122 126 (Pubitemid 19025917)
25. A.M. Goorin, J.J. Shuster, and A. Baker Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study1 J Clin Oncol 9 4 1991 600 605
26. G. Bacci, S. Ferrari, and A. Longhi Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy9 Eur J Cancer 37 1 2001 32 38 (Pubitemid 32119357)
27. A. Lindbom, G. Soderberg, and H.J. Spjut Osteosarcoma. A review of 96 cases Acta Radiol 56 1961 1 19
28. L.E.E. ES, and D.H. Mackenzie Osteosarcoma. A study of the value of preoperative megavoltage radiotherapy Br J Surg 51 1964 252 274
29. R.C. Marcove, V. Mike, J.V. Hajek, A.G. Levin, and R.V. Hutter Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases J Bone Joint Surg Am 52 3 1970 411 423
30. R. Gaffney, K.K. Unni, and F.H. Sim Follow-up study of long-term survivors of osteosarcoma in the prechemotherapy era Hum Pathol 37 8 2006 1009 1014 (Pubitemid 44080805)
31. E. Poppe, K. Liverud, and J. Efskind Osteosarcoma Acta Chir Scand 134 7 1968 549 556
32. C.H. Price, and G.M. Jeffree Metastatic spread of osteosarcoma Br J Cancer 28 6 1973 515 524
33. G. Bonadonna, S. Monfardini, L.M. De, F. Fossati-Bellani, and G. Beretta Phase I and preliminary phase II evaluation of adriamycin (NSC 123127) Cancer Res 30 10 1970 2572 2582
34. E. Middleman, J. Luce, and E. Frei III Clinical trials with adriamycin Cancer 28 4 1971 844 850
35. J.J. Wang, E. Cortes, L.F. Sinks, and J.F. Holland Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease Cancer 28 4 1971 837 843
36. E.P. Cores, J.F. Holland, J.J. Wang, and L.F. Sinks Doxorubicin in disseminated osteosarcoma JAMA 221 10 1972 1132 1138
37. M.A. Friedman, and S.K. Carter The therapy of osteogenic sarcoma: current status and thoughts for the future J Surg Oncol 4 5 1972 482 510
38. R.M. O'Bryan, J.K. Luce, and R.W. Talley Phase II evaluation of adriamycin in human neoplasia Cancer 32 1 1973 1 8
39. C. Tan, E. Etcubanas, and N. Wollner Adriamycin - an antitumor antibiotic in the treatment of neoplastic diseases Cancer 1 1973 9 17
40. R.S. Benjamin, P.H. Wiernik, and N.R. Bachur Adriamycin chemotherapy-efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule Cancer 33 1 1974 19 27
41. C.B. Pratt, and E.C. Shanks Doxorubicin in treatment of malignant solid tumors in children Am J Dis Child 127 4 1974 534 536
42. A.H. Ragab, W.W. Sutow, and D.M. Komp Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study Cancer 36 5 1975 1567 1576
43. J.J. van Dyk, A.M. van der Merwe, H.C. Falkson, and G. Falkson Adriamycin in the treatment of cancer S Afr Med J 50 3 1976 61 66
44. D.A. Schoenfeld, C. Rosenbaum, and J. Horton A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma Cancer 50 12 1982 2757 2762 (Pubitemid 13220781)
45. N. Niederle, M.E. Scheulen, and M. Cremer Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas Cancer Treat Rev 10 Suppl. A 1983 129 135 (Pubitemid 14249409)
46. K.H. Antman, D. Montella, C. Rosenbaum, and M. Schwen Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma Cancer Treat Rep 69 5 1985 499 504 (Pubitemid 15031398)
47. C. Marti, T. Kroner, and W. Remagen High-dose ifosfamide in advanced osteosarcoma Cancer Treat Rep 69 1 1985 115 117 (Pubitemid 15197088)
48. I. Magrath, J. Sandlund, and A. Raynor A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people Cancer Chemother Pharmacol 18 Suppl. 2 1986 S25 S28
49. K.H. Antman, L. Ryan, A. Elias, D. Sherman, and H.E. Grier Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma J Clin Oncol 7 1 1989 126 131 (Pubitemid 19089091)
50. C.R. Pinkerton, and J. Pritchard A phase II study of ifosfamide in paediatric solid tumours Cancer Chemother Pharmacol 24 Suppl. 1 1989 S13 S15
51. E. Schwartzman, M. Scopinaro, and N. Angueyra Phase II study of ifosfamide as a single drug for relapsed paediatric patients Cancer Chemother Pharmacol 24 Suppl. 1 1989 S11 S12
52. Chawla SP, Rosen G, Lowenbraun S, Morton D, Eilber F. Role of high dose ifosphamide (HDI) in recurent osteosarcoma. ASCO Annual Meeting Proceedings 1990;9:310.
53. R.S. Benjamin, S.S. Legha, S.R. Patel, and C. Nicaise Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience Cancer Chemother Pharmacol 31 Suppl. 2 1993 S174 S179
54. M.B. Harris, A.B. Cantor, and A.M. Goorin Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study Med Pediatr Oncol 24 2 1995 87 92
55. I. Gullu, S. Yalcin, and G. Tekuzman High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas Cancer Invest 14 3 1996 239 242 (Pubitemid 26273561)
56. Picci P, Bacci G, Ferrari S, Comandone A, Tienghi A. Salvage treatment with high dose ifosfamide and surgery for osteosarcoma patients relapsed with lung metastases. Preliminary Results. ASCO Annual Meeting Proceedings 1996;14:459.
57. C.B. Pratt, X. Luo, and L. Fang Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience Med Pediatr Oncol 27 3 1996 145 148 (Pubitemid 26282093)
58. S.G. Berrak, M. Pearson, S. Berberoglu, I.E. Ilhan, and N. Jaffe High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity Pediatr Blood Cancer 44 3 2005 215 219 (Pubitemid 40209429)
59. C. Meazza, M. Casanova, and R. Luksch Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma Pediatr Blood Cancer 55 4 2010 617 620
60. N. Jaffe, D. Paed, and S. Farber Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy Cancer 31 6 1973 1367 1373
61. N. Jaffe Progress report on high-dose methotrexate (NSC-740) with citrovorum rescue in the treatment of metastatic bone tumors Cancer Chemother Rep 58 2 1974 275 280
62. C.B. Pratt, D. Roberts, E.C. Shanks, and E.L. Warmath Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-"leucovorin rescue" for children with malignant tumors Cancer Res 34 12 1974 3326 3331
63. E.P. Ambinder, M. Perloff, T. Ohnuma, H.F. Biller, and J.F. Holland High dose methotrexate followed by citrovorum factor reversal in patients with advanced cancer Cancer 43 4 1979 1177 1182 (Pubitemid 9180281)
64. Rosen G, Nirenberg A, Juergens H, Caparros B, Huvos AG. Response of primary osteogenic sarcoma to single agent therapy with high-dose methotrexate with citrovorum factor rescue. In: Current chemotherapy and infectious diseases. Proceedings of the 11th international congress of chemotherapy and the 19th interscience conference on antimicrobial agents and chemotherapy; 1979. p.1633-5.
65. E. Frei III, R.H. Blum, and S.W. Pitman High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity Am J Med 68 3 1980 370 376 (Pubitemid 10130377)
66. C.B. Pratt, C. Howarth, and J.L. Ransom High-dose methotrexate used alone and in combination for measurable primary or metastatic osteosarcoma Cancer Treat Rep 64 1 1980 11 20 (Pubitemid 10125447)
67. K. Kimura High-dose methotrexate for adult malignancies Experimental and clinical results. Cancer Bulletin 33 1981 67 71
68. N. Jaffe, R. Bowman, and Y.M. Wang Chemotherapy for primary osteosarcoma by intra-arterial infusion. Review of the literature and comparison with results achieved by the intravenous route Cancer Bulletin 36 1 1984 37 42 Date of Publication: 1984 (Pubitemid 14142904)
69. N. Jaffe, R. Robertson, and A. Ayala Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma J Clin Oncol 3 8 1985 1101 1104 (Pubitemid 15004831)
70. D.J. Wagener, A.T. Van Oosterom, and J.H. Mulder Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer Cancer Treat Rep 70 5 1986 615 618 (Pubitemid 16121009)
71. R. Nitschke, K.A. Starling, T. Vats, and H. Bryan Cis- diamminedichloroplatinum (NSC-119875) in childhood malignancies: a Southwest Oncology Group study Med Pediatr Oncol 4 2 1978 127 132 (Pubitemid 8345617)
72. J.J. Ochs, A.I. Freeman, and H.O. Douglass Jr. Cis- Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma Cancer Treat Rep 62 2 1978 239 245
73. E.S. Baum, P. Gaynon, L. Greenberg, W. Krivit, and D. Hammond Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report Cancer Treat Rep 65 9-10 1981 815 822 (Pubitemid 11050878)
74. G.M. Mavligit, R. Benjamin, and Y.Z. Patt Intraarterial cis-platinum for patients with inoperable skeletal tumors Cancer 48 1 1981 1 4 (Pubitemid 11064368)
75. N. Jaffe, J. Knapp, and V.P. Chuang Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies Cancer 51 3 1983 402 407 (Pubitemid 13185366)
76. M. Gasparini, J. Rouesse, and O.A. van Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group Cancer Treat Rep 69 2 1985 211 213
77. C.B. Pratt, J.E. Champion, and N. Senzer Treatment of unresectable or metastatic osteosarcoma with cisplatin or cisplatin-doxorubicin Cancer 56 8 1985 1930 1933 (Pubitemid 15240861)
78. S. Abe, Y. Nishimoto, K. Isu, T. Ishii, and T. Goto Preoperative cisplatin for initial treatment of limb osteosarcoma: its local effect and impact on prognosis Cancer Chemother Pharmacol 50 4 2002 320 324
79. R.L. Chard Jr., W. Krivit, W.A. Bleyer, and D. Hammond Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report Cancer Treat Rep 63 11-12 1979 1755 1759 (Pubitemid 10138927)
80. N.I. Nissen, T.F. Pajak, and L.A. Leone Clinical trial of VP 16-213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B Cancer 45 2 1980 232 235 (Pubitemid 10212184)
81. P.J. O'Dwyer, B. Leyland-Jones, M.T. Alonso, S. Marsoni, and R.E. Wittes Etoposide (VP-16-213). Current status of an active anticancer drug N Engl J Med 312 11 1985 692 700 (Pubitemid 15134707)
82. F. Kung, F.A. Hayes, and J. Krischer Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group Invest New Drugs 6 1 1988 31 36
83. G. Rosen, M.L. Murphy, A.G. Huvos, M. Gutierrez, and R.C. Marcove Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma Cancer 37 1 1976 1 11
84. G. Rosen, R.C. Marcove, and B. Caparros Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery Cancer 43 1979 2163 2177 (Pubitemid 9246383)
85. G. Rosen, A. Nirenberg, and B. Caparros Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination chemotherapy (T-7) Natl Cancer Inst Monogr 56 1981 213 220 (Pubitemid 12193863)
86. G. Rosen, B. Caparros, and A.G. Huvos Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy Cancer 49 6 1982 1221 1230 (Pubitemid 12187826)
87. G. Rosen, R.C. Marcove, and A.G. Huvos Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy J Cancer Res Clin Oncol 106 Suppl. 1983 55 67 (Pubitemid 13040824)
88. P.A. Meyers, G. Heller, and J. Healey Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience J Clin Oncol 10 1 1992 5 15
89. P.A. Meyers, R. Gorlick, and G. Heller Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol J Clin Oncol 16 7 1998 2452 2458 (Pubitemid 28309040)
90. M. Hudson, M.R. Jaffe, and N. Jaffe Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience J Clin Oncol 8 12 1990 1988 1997
91. N. Jaffe, H. Carrasco, K. Raymond, A. Ayala, and F. Eftekhari Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer 95 10 2002 2202 2210 (Pubitemid 35253383)
92. N. Jaffe, D. Smith, and M.R. Jaffe Intraarterial cisplatin in the management of stage IIB osteosarcoma in the pediatric and adolescent age group Clin Orthop Relat Res 270 1991 15 21
93. J.S. Miser, and M. Krailo Osteosarcoma in adolescents and young adults: new developments and controversies. The Children's Cancer Group (CCG) studies Cancer Treat Res 62 1993 287 291
94. A.J. Provisor, L.J. Ettinger, and J.B. Nachman Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group J Clin Oncol 15 1 1997 76 84 (Pubitemid 27020560)
95. A.M. Goorin, D.J. Schwartzentruber, and M. Devidas Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651 J Clin Oncol 21 8 2003 1574 1580 (Pubitemid 46594112)
96. M.M. Zalupski, C. Rankin, and J.R. Ryan Adjuvant therapy of osteosarcoma-A Phase II trial: Southwest Oncology Group study 9139 Cancer 100 4 2004 818 825 (Pubitemid 38176862)
97. P.A. Meyers, C.L. Schwartz, and M. Krailo Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate J Clin Oncol 23 9 2005 2004 2011 (Pubitemid 46211380)
98. P.A. Meyers, C.L. Schwartz, and M.D. Krailo Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group J Clin Oncol 26 4 2008 633 638 (Pubitemid 351264359)
99. S. Hunsberger, B. Freidlin, and M.A. Smith Complexities in interpretation of osteosarcoma clinical trial results J Clin Oncol 26 18 2008 3103 3104
100. A.S. Petrilli, C.B. de, and V.O. Filho Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival J Clin Oncol 24 7 2006 1161 1168 (Pubitemid 46638814)
101. K. Winkler, G. Beron, and R. Kotz Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study J Cancer Res Clin Oncol 106 Suppl. 1983 1 7 (Pubitemid 13040813)
102. K. Winkler, G. Beron, and R. Kotz Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study J Clin Oncol 2 6 1984 617 624 (Pubitemid 14025617)
103. K. Winkler, G. Beron, and G. Delling Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response J Clin Oncol 6 2 1988 329 337 (Pubitemid 18065939)
104. K. Winkler, S.S. Bielack, and G. Delling Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS) Cancer Treat Res 62 1993 269 277
105. N. Fuchs, S.S. Bielack, and D. Epler Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs Ann Oncol 9 8 1998 893 899 (Pubitemid 28440449)
106. K. Winkler, S. Bielack, and G. Delling Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86) Cancer 66 8 1990 1703 1710 (Pubitemid 20381203)
107. G. Bacci, P. Picci, and P. Ruggieri Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin Cancer 65 11 1990 2539 2553 (Pubitemid 20168944)
108. S. Ferrari, G. Bacci, and P. Picci Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy Ann Oncol 8 1997 765 771 (Pubitemid 27397900)
109. G. Bacci, P. Picci, and G. Pignatti Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities Clin Orthop Relat Res 270 1991 87 98
110. G. Bacci, P. Picci, and S. Ferrari Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy Cancer 71 1993 1224 1230 (Pubitemid 23054910)
111. S. Ferrari, M. Mercuri, and P. Picci Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response Tumori 85 6 1999 458 464 (Pubitemid 30074592)
112. G. Bacci, A. Briccoli, and S. Ferrari Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol Eur J Cancer 37 16 2001 2030 2039 (Pubitemid 32938106)
113. G. Bacci, S. Ferrari, and A. Longhi High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study J Chemother 14 2 2002 198 206 (Pubitemid 34460560)
114. S. Ferrari, S. Smeland, and M. Mercuri Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups J Clin Oncol 23 34 2005 8845 8852 (Pubitemid 46211531)
115. G. Bacci, S. Ferrari, and A. Tienghi A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity Eur J Surg Oncol 27 1 2001 98 104 (Pubitemid 32229702)
116. G. Saeter, T.A. Alvegard, and I. Elomaa Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study J Clin Oncol 9 10 1991 1766 1775
117. G. Saeter, T. Wiebe, and T. Wiklund Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience Acta Orthop Scand Suppl 285 1999 74 82 (Pubitemid 29329084)
118. S. Smeland, C. Muller, and T.A. Alvegard Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders Eur J Cancer 39 4 2003 488 494 (Pubitemid 36173693)
119. V.H. Bramwell, M. Burgers, and R. Sneath A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup J Clin Oncol 10 10 1992 1579 1591 (Pubitemid 23057988)
120. R.L. Souhami, A.W. Craft, and J.W.vd Eijken Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup Lancet 350 1997 911 917 (Pubitemid 27420527)
121. I.J. Lewis, M.A. Nooij, and J. Whelan Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup J Natl Cancer Inst 99 2 2007 112 128
122. C. Kalifa, H. Razafindrakoto, and G. Vassal Chemotherapy in osteogenic sarcoma: the experience of the Pediatric Department of the Gustave Roussy Institute Cancer Treat Res 62 1993 347 349
123. T. Philip, C. Iliescu, and M.C. Demaille High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]-doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Federation Nationale des Centres de Lutte contre le Cancer and Societe Francaise d'Oncologie Pediatrique Ann Oncol 10 9 1999 1065 1071
124. M.C. Le Deley, J.M. Guinebretiere, and J.C. Gentet SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients Eur J Cancer 43 4 2007 752 761
125. P.U. Tunn, and P. Reichardt Chemotherapy for osteosarcoma without high-dose methotrexate: a 12-year follow-up on 53 patients Onkologie 30 5 2007 228 232 (Pubitemid 46674904)
126. G. Bacci, P. Picci, and S. Ferrari Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies J Chemother 5 4 1993 237 246 (Pubitemid 23309982)
127. A. Kawai, S. Sugihara, T. Kunisada, M. Hamada, and H. Inoue The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma Arch Orthop Trauma Surg 115 2 1996 68 70 (Pubitemid 26041340)
128. S. Leung, G.M. Marshall, and M.A. al Mahr Prognostic significance of chemotherapy dosage characteristics in children with osteogenic sarcoma Med Pediatr Oncol 28 3 1997 179 182 (Pubitemid 27078418)
129. I.J. Lewis, S. Weeden, D. Machin, D. Stark, and A.W. Craft Received dose and dose intensity of chemotherapy and outcome in non-metastatic extremity osteosarcoma J Clin Oncol 18 24 2000 4028 4037 (Pubitemid 32038394)
130. G. Bacci, S. Ferrari, and F. Bertoni Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report J Clin Oncol 18 24 2000 4016 4027 (Pubitemid 32038393)
131. N. Jaffe Pediatric osteosarcoma: treatment of the primary tumor with intraarterial cis-diamminedichloroplatinum-II (CDP)-advantages, disadvantages, and controversial issues Cancer Treat Res 62 1993 75 84
132. J.W. Cullen, B.A. Jamroz, and S.L. Stevens The value of serial arteriography in osteosarcoma: delivery of chemotherapy, determination of therapy duration, and prediction of necrosis J Vasc Interv Radiol 16 8 2005 1107 1119 (Pubitemid 41177124)
133. R.R. Hugate, R.M. Wilkins, and C.M. Kelly Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults Clin Orthop Relat Res 466 6 2008 1292 1301
134. S.S. Bielack, P. Bieling, R. Erttmann, and K. Winkler Intraarterial chemotherapy for osteosarcoma: does the result really justify the effort? Cancer Treat Res 62 1993 85 92
135. S. Bielack, B. Kempf-Bielack, and D. Schwenzer Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients Klin Padiatr 211 4 1999 260 270 (Pubitemid 29364766)
136. M. Eselgrim, H. Grunert, and T. Kuhne Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials Pediatr Blood Cancer 47 1 2006 42 50 (Pubitemid 43787907)
137. G. Bacci, A. Longhi, and M. Versari Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution Cancer 106 5 2006 1154 1161
138. A. Nardin, M.L. Lefebvre, K. Labroquere, O. Faure, and J.P. Abastado Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma Curr Cancer Drug Targets 6 2 2006 123 133
139. E.P. Buddingh, M.L. Kuijjer, and R.A. Duim Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage-activating agents Clin Cancer Res 17 8 2011 2110 2119
140. C.R. Muller, S. Smeland, H.C. Bauer, G. Saeter, and H. Strander Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series Acta Oncol 44 5 2005 475 480 (Pubitemid 41191780)
141. J. Whelan, D. Patterson, and M. Perisoglou The role of interferons in the treatment of osteosarcoma Pediatr Blood Cancer 54 3 2010 350 354
142. P. Anderson, L. Kopp, and N. Anderson Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma) Expert Opin Investig Drugs 17 11 2008 1703 1715